成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. PI3K/Akt/mTOR Autophagy Immunology/Inflammation Apoptosis Cell Cycle/DNA Damage Anti-infection Metabolic Enzyme/Protease
  3. mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
  4. Rapamycin

Rapamycin  (Synonyms: 雷帕霉素; 西羅莫司; Sirolimus; AY-22989)

目錄號(hào): HY-10219 純度: 99.94%
COA 產(chǎn)品使用指南

Rapamycin (Sirolimus) 是一種有效且特異性的 mTOR 抑制劑，作用于 HEK293 細(xì)胞，抑制 mTOR，IC50 為 0.1 nM。Rapamycin 與 FKBP12 結(jié)合且抑制 mTORC1。Rapamycin 還是一種自噬 (autophagy) 激活劑，免疫抑制劑。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Rapamycin Chemical Structure

Rapamycin Chemical Structure

CAS No. : 53123-88-9

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥605
In-stock
5 mg ￥343
In-stock
10 mg ￥550
In-stock
25 mg ￥750
In-stock
50 mg ￥1100
In-stock
100 mg ￥1500
In-stock
500 mg ￥3800
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Rapamycin:

MCE 顧客使用本產(chǎn)品發(fā)表的 890 篇科研文獻(xiàn)

WB
IHC
IF

    Rapamycin purchased from MCE. Usage Cited in: J Hazard Mater. 2023 Jul 5,453,131354.

    Rapamycin (50 nM; 24 h) partially reverses the cobalt-induced increase in LC3B-II and p62 levels in H4 cells.

    Rapamycin purchased from MCE. Usage Cited in: J Hazard Mater. 2023 Jul 5,453,131354.

    Rapamycin (50?nM; 24 h) efficiently inhibits the Cobalt-induced hyperphosphorylation of Tau in Ser262 and Thr181, when in H4 cells.

    Rapamycin purchased from MCE. Usage Cited in: PLoS Pathog. 2023 Mar 27;19(3):e1011295.  [Abstract]

    Rapamycin (100 nM; 24 h) increases PRRSV replication in Marc-145 cells.

    Rapamycin purchased from MCE. Usage Cited in: Cancer Cell Int. 2023 Apr 16;23(1):68.  [Abstract]

    Rapamycin (2.5 mM; 24 h) ignificantly reverses the PCK1-sh-induced decreased expression of LC3B-II in SW480-sh cells.

    Rapamycin purchased from MCE. Usage Cited in: Cell Death Dis. 2020 Jun 12;11(6):454.  [Abstract]

    Immunofluorescence staining of p62 is conducted in HSC-T6 cells. G-Rg3 pretreatment with 16?μM and Ra are conducted with 100 or 200?nM.

    Rapamycin purchased from MCE. Usage Cited in: Nature. 2018 Jun;558(7711):540-546.  [Abstract]

    Western blot and quantification of P-AKT (Ser473) and P-S6RP in the liver, heart and muscle, respectively, of PIK3CAWT and PIK3CACAGG-CreER mice treated with vehicle or Rapamycin directly after Cre induction.

    Rapamycin purchased from MCE. Usage Cited in: Acta Biomater. 2018 Nov;81:278-292.  [Abstract]

    Evident LC3 turnover and increased level of Atg5 are found upon Rapamycin treatment, which indicate significant autophagy activation.

    Rapamycin purchased from MCE. Usage Cited in: Int J Cancer. 2018 Aug 15;143(4):931-943.  [Abstract]

    H1975 cells are pretreated with Rapamycin (100 nM) for 1 h and then cells are exposed to IFN-γ (100 U/mL). Phosphorylation of AKT, S6, 4E-BP1 are analyzed by western blotting.

    Rapamycin purchased from MCE. Usage Cited in: Sci Rep. 2018 Mar 7;8(1):4108.  [Abstract]

    L02 cells exposed to PA (200 μM) with different concentrations of Rapamycin (Rapa) or Chloroquine (CQ) for 24 h. Palmitate (PA) induced higher protein expression of LC3 II/I and p62 compared with control as indicated by western blot.

    Rapamycin purchased from MCE. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):144-155.  [Abstract]

    Raw264.7 macrophages treated without or with Rapamycin (1 μΜ) or Chloroquine (20 μΜ) for 48 h. Western blot shows the protein expression levels of Atg5, Beclin1, LC3, and p62/SQSMT1.

    Rapamycin purchased from MCE. Usage Cited in: Pharmacol Biochem Behav. 2019 Feb;177:1-11.  [Abstract]

    Effect of treatment with Rapamycin, trehalose, or their combination on tyrosine hydroxylase (TH) expression in the striatum in MPTP-induced mouse model of Parkinson’s disease.

    Rapamycin purchased from MCE. Usage Cited in: Pharmacol Biochem Behav. 2019 Feb;177:1-11.  [Abstract]

    Effect of treatment with Rapamycin, trehalose, or their combination on autophagy activity measured by quantified immunoreactivity of LC3-II in the s. nigra. MPTP is administered at the dose of 20 mg/kg (i.p., daily) for 4 days to induce PD-like pathology.

    Rapamycin purchased from MCE. Usage Cited in: Biotechnol Appl Biochem. 2018 Sep;65(5):665-671.  [Abstract]

    The mTOR inhibitor Rapamycin augments the autophagy induced by GEM. (A, B) Beclin-1 and LC3B expression is analyzed by western blot after treatment of the cells with GEM (5 μM) and Rapamycin (0, 1, and 2.5 μM) for 48 (A) or 72 (B) h.

    Rapamycin purchased from MCE. Usage Cited in: PeerJ. 2018 Nov 21;6:e5988.  [Abstract]

    C6/36 cells are treated with 3-MA, Rapa or CQ for 36 h, 6 h and 36 h, respectively. For Rapa plus CQ treatment, C6/36 cells are treated with CQ for 30 h then treated with Rapa for 6 h. Mock and DMSO treated C6/36 cells are used as controls. After the treatment, the levels of AaAtg8-I and AaAtg8-II are analysed by immunoblotting using antibody against AaAtg8.

    Rapamycin purchased from MCE. Usage Cited in: PeerJ. 2018 Nov 21;6:e5988.  [Abstract]

    C6/36 cells are treated with 3-MA, Rapa or CQ for 36 h, 6 h and 36 h, respectively and then subjected to MDC staining. Mock and DMSO treated C6/36 cells are used as controls.

    Rapamycin purchased from MCE. Usage Cited in: Int J Ophthalmol. 2018 May 18;11(5):712-718.  [Abstract]

    Western blotting shows that Rapamycin treatment downregulates p-mTOR protein levels in infected and uninfected corneal tissues compared to the vehicle group.

    Rapamycin purchased from MCE. Usage Cited in: Evid Based Complement Alternat Med. 2018 Jun 26;2018:6049498.  [Abstract]

    Western blot analysis of AKT, p-Akt, mTOR, p-mTOR, FOXO1 and p-FOXO1 expression in U-87 MG cells after treatment with LY294002 (20 μM), Rapamycin (50 nM) or NAC (5 mM) with or without Xihuang pill (XHP).

    Rapamycin purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;48(6):2318-2336.  [Abstract]

    Cells are pretreated with 5 mM 3-MA or 2 μM for 1 h and then exposed to 40 μM EPA and 10 μM Rp for 48 h. Cell extracts are prepared and subjected to western blot analysis.

    Rapamycin purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;48(6):2318-2336.  [Abstract]

    Cells are treated with Rapamycin (Rp; 10 μM)+Eicosapentaenoic acid (EPA; 40 μM) with or without Chloroquine (CQ; 5 μM) for 48 h. Cell extracts are prepared and subjected to western blot analysis.

    Rapamycin purchased from MCE. Usage Cited in: J Clin Invest. 2017 Sep 1;127(9):3339-3352.  [Abstract]

    Phosphorylation of SMAD1/5/8 and SMAD2/3 in FOP-iMSCs. Serum-starved FOP-iMSCs are pretreated with 10 nM Rapamycin (Rapa), 1 μM DMH1, or 1 μM SB-431542 for 1 hour.

    Rapamycin purchased from MCE. Usage Cited in: Nat Commun. 2017 Jun 8;8:15617.  [Abstract]

    Immunoblot analysis of KRAS protein levels in parental (P) and resistant derivatives (R1 and R2) following 4?h treatment with the corresponding inhibitors Rapamycin, AZD2014, MLN0128, BEZ235 and 4EGI-1. Images are cropped for clarity from the same exposure of the same membrane.

    Rapamycin purchased from MCE. Usage Cited in: PLoS One. 2017 Nov 29;12(11):e0188748.  [Abstract]

    FTY720 reverses activation of autophagy induced by mTOR inhibitor, rapamycin. The impact of FTY720 and Rapamycin on the expression of Beclin1 and LC3 is evaluated by western blotting. Results are representative of 4 independent experiments.

    Rapamycin purchased from MCE. Usage Cited in: PLoS One. 2017 Jun 21;12(6):e0179772.  [Abstract]

    RAW264.7 cells transfected with miR-144-3p control or miR-144-3p mimic in full medium with or without 50μg/mL Rapamycin or 0.1% DMSO. 50 μg of total cell extracts are analyzed by Western blotting with a mouse anti-SQSTM1/p62 antibody. The p62 levels are detected by Western-blot (upper). Quantitative analysis of the p62 band normalized to β-actin is shown (lower).

    Rapamycin purchased from MCE. Usage Cited in: Biochem Pharmacol. 2016 Dec 15;122:42-61.  [Abstract]

    Inhibition of SREBPs processing by AHI is dependent on LKB-1/AMPK/mTOR pathway. (A) HepG2 cells are incubated with or without MHY1485 or Rapamycin for 1 h, the cells are switched to medium D in the presence of vehicle, or AHI. (B) HepG2 cells are incubated with or without Compound C for 1 h, the cells are switched to medium D in the presence of vehicle, or AHI.

    Rapamycin purchased from MCE. Usage Cited in: Sci Bull. 2015 Dec;60(24):2120-2128.

    CNE-2Z cells are treated with AZD8055 or Rapamycin with or without 1 T SMF for 3 d before they are harvested for Western blot.

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

    IC50 & Target[1][2]

    mTOR

    0.1 nM (IC50, in HEK293 cells )

    Microbial Metabolite

     

    Autophagy

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    18.74 μM
    Compound: Rapamycin
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 31546197]
    A549 IC50
    30.72 μM
    Compound: Rapamycin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33862514]
    A549 IC50
    49.35 μM
    Compound: Rapamycin
    Antitumor activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo assay
    Antitumor activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by Cell Titer-Glo assay
    		[PMID: 35688004]
    HEK293 EC50
    0.05 μM
    Compound: Rapamycin
    Inhibition of TPA-induced degradation of Pdcd4 (amino acid 39-91) expressed in human HEK293 cells assessed as minimum compound concentration required for 50% recovery of Pdcd4-luciferase signal incubated for 8 hrs by luciferase reporter gene assay
    Inhibition of TPA-induced degradation of Pdcd4 (amino acid 39-91) expressed in human HEK293 cells assessed as minimum compound concentration required for 50% recovery of Pdcd4-luciferase signal incubated for 8 hrs by luciferase reporter gene assay
    		[PMID: 21539301]
    HEK293 IC50
    0.1 nM
    Compound: rapamycin
    Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis
    Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis
    		[PMID: 17350953]
    HEK-293T EC50
    0.1 nM
    Compound: RAPA
    Antiviral activity against HIV1 R5 assessed as inhibition of cell-cell fusion between R5-envelope expressing HEK293T cells and CD8 depleted human PBMCs pretreated for 6 days
    Antiviral activity against HIV1 R5 assessed as inhibition of cell-cell fusion between R5-envelope expressing HEK293T cells and CD8 depleted human PBMCs pretreated for 6 days
    		[PMID: 17485501]
    HEK-293T EC50
    1.3 nM
    Compound: RAPA
    Antiviral activity against HIV1 X4 assessed as inhibition of cell-cell fusion between X4-envelope expressing HEK293T cells and CD8 depleted human PBMCs pretreated for 6 days
    Antiviral activity against HIV1 X4 assessed as inhibition of cell-cell fusion between X4-envelope expressing HEK293T cells and CD8 depleted human PBMCs pretreated for 6 days
    		[PMID: 17485501]
    HeLa IC50
    > 10000 nM
    Compound: Rapamycin
    Growth inhibition of human HeLa cells after 72 hrs by CCK8 assay
    Growth inhibition of human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    HepG2 EC50
    10 μM
    Compound: Sirolimus
    Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
    Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
    		[PMID: 20966043]
    HepG2 CC50
    67.2 μM
    Compound: 78
    Cytotoxicity against human HepG2 assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
    Cytotoxicity against human HepG2 assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
    		[PMID: 28051303]
    MCF7 EC50
    < 1 nM
    Compound: Rapamycin
    Cytotoxicity against human MCF7 cells after 5 days by Presto blue reagent-based fluorescence analysis
    Cytotoxicity against human MCF7 cells after 5 days by Presto blue reagent-based fluorescence analysis
    		10.1039/C5MD00493D
    MCF7 IC50
    18.74 μM
    Compound: Rapamycin
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    4980 nM
    Compound: Rapamycin
    Growth inhibition of human MCF7 cells after 72 hrs by CCK8 assay
    Growth inhibition of human MCF7 cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    MDA-MB-231 GI50
    > 100 nM
    Compound: Rapamycin
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 32510949]
    MDA-MB-231 IC50
    > 10000 nM
    Compound: Rapamycin
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by CCK8 assay
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    MDA-MB-231 IC50
    0.9 μM
    Compound: Rapamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    35.79 μM
    Compound: Rapamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33862514]
    MDA-MB-453 GI50
    0.05 nM
    Compound: Rapamycin
    Antiproliferative activity against human MDA-MB-453 cells incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-453 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 32510949]
    MDA-MB-468 IC50
    37.2 μM
    Compound: Rapamycin
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33862514]
    MEF IC50
    0.05 nM
    Compound: Sirolimus
    Inhibition of mTOR in mouse TSC1-/- MEF cells assessed as inhibition of S6 Ser240/244 phosphorylation incubated for 2 hrs by fluorescence based assay
    Inhibition of mTOR in mouse TSC1-/- MEF cells assessed as inhibition of S6 Ser240/244 phosphorylation incubated for 2 hrs by fluorescence based assay
    		[PMID: 31223435]
    MV4-11 IC50
    > 500 nM
    Compound: RAPA
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    		[PMID: 30629434]
    NCI-H460 IC50
    > 10000 nM
    Compound: Rapamycin
    Growth inhibition of human H460 cells after 72 hrs by CCK8 assay
    Growth inhibition of human H460 cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    OCI-AML2 IC50
    > 500 nM
    Compound: RAPA
    Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human OCI-AML2 cells after 72 hrs by MTT assay
    		[PMID: 30629434]
    OCI-AML-3 IC50
    > 500 nM
    Compound: RAPA
    Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay
    		[PMID: 30629434]
    OVCAR-5 IC50
    > 10000 nM
    Compound: Rapamycin
    Growth inhibition of human OVCAR5 cells after 72 hrs by CCK8 assay
    Growth inhibition of human OVCAR5 cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    PC-3 EC50
    43.1 μM
    Compound: Rapamycin
    Cytotoxicity against human PC3 cells by MTT assay
    Cytotoxicity against human PC3 cells by MTT assay
    		[PMID: 28774426]
    SiHa IC50
    1756 nM
    Compound: Rapamycin
    Growth inhibition of human SiHa cells after 72 hrs by CCK8 assay
    Growth inhibition of human SiHa cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    SK-OV-3 IC50
    > 10000 nM
    Compound: Rapamycin
    Growth inhibition of human SKOV3 cells after 72 hrs by CCK8 assay
    Growth inhibition of human SKOV3 cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    SUM185PE GI50
    0.04 nM
    Compound: Rapamycin
    Antiproliferative activity against human SUM185PE cells incubated for 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SUM185PE cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 32510949]
    T47D IC50
    1576 nM
    Compound: Rapamycin
    Growth inhibition of human T47D cells after 72 hrs by CCK8 assay
    Growth inhibition of human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 29308895]
    體外研究
    (In Vitro)

    Rapamycin（12.5-100 nM；24 小時(shí)）處理在所有測試的細(xì)胞系（A549、SPC-A-1、95D 和 NCI-H446 細(xì)胞）中以劑量依賴性方式對(duì)肺癌細(xì)胞增殖產(chǎn)生適度抑制作用，達(dá)到約 100 nM 時(shí)細(xì)胞增殖減少 30-40%，而 12.5 nM 時(shí)減少約 10%[3]。
    將肺癌細(xì)胞系 95D 細(xì)胞單獨(dú)或聯(lián)合暴露于 Rapamycin（10 nM、20 nM）和 RP-56976（1 nM、10 nM）（Rapamycin 20 nM + RP-56976 10 nM）。單獨(dú)暴露于 Rapamycin 或 RP-56976 24 小時(shí)后，不會(huì)顯著改變 ERK1/2 的表達(dá)或磷酸化水平，而 Rapamycin 與 RP-56976 聯(lián)合處理的細(xì)胞表現(xiàn)出 ERK1/2 磷酸化水平的顯著降低[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[3]

    Cell Line: Lung cancer cell lines A549, SPC-A-1, 95D and NCI-H446
    Concentration: 12.5 nM, 25 nM, 50 nM, 100 nM
    Incubation Time: 24 hours
    Result: Treatment exerted modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines.

    Western Blot Analysis[3]

    Cell Line: 95D cells
    Concentration: 10 nM and 20 nM
    Incubation Time: 24 hours
    Result: Combination treatment with RP-56976 decreased phosphorylation of ERK.
    體內(nèi)研究
    (In Vivo)

    Rapamycin (2.0 mg/kg; 腹腔內(nèi)注射; 每隔一天;28 天) 單獨(dú)使用有中等的抑制作用。然而，與對(duì)照組、Rapamycin 組相比，二甲雙胍聯(lián)合 Rapamycin 對(duì)腫瘤生長的抑制作用明顯增強(qiáng)[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 24 male nu/nu mice aged 4-5 week old (15-20 g)[4]
    Dosage: 2.0 mg/kg
    Administration: Intraperitoneal injection; every other day; 28 days
    Result: Had a moderate inhibitory effect in monotherapy group. The combination with Metformin exerted a significantly increased inhibition of tumor growth.
    Clinical Trial
    分子量

    914.17

    Formula

    C51H79NO13
    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    雷帕霉素；西羅莫司
    結(jié)構(gòu)分類
    初始來源

    bacterium Streptomyces hygroscopicus
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 125 mg/mL (136.74 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

    Ethanol 中的溶解度 : 50 mg/mL (54.69 mM; 超聲助溶)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.0939 mL 5.4694 mL 10.9389 mL
    5 mM 0.2188 mL 1.0939 mL 2.1878 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.73 mM); 懸濁液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 EtOH 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑： 10% EtOH    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (2.73 mM); 懸濁液; 超聲助溶

      此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 EtOH 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.94%

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 1.0939 mL 5.4694 mL 10.9389 mL 27.3472 mL
    5 mM 0.2188 mL 1.0939 mL 2.1878 mL 5.4694 mL
    10 mM 0.1094 mL 0.5469 mL 1.0939 mL 2.7347 mL
    15 mM 0.0729 mL 0.3646 mL 0.7293 mL 1.8231 mL
    20 mM 0.0547 mL 0.2735 mL 0.5469 mL 1.3674 mL
    25 mM 0.0438 mL 0.2188 mL 0.4376 mL 1.0939 mL
    30 mM 0.0365 mL 0.1823 mL 0.3646 mL 0.9116 mL
    40 mM 0.0273 mL 0.1367 mL 0.2735 mL 0.6837 mL
    50 mM 0.0219 mL 0.1094 mL 0.2188 mL 0.5469 mL
    DMSO 60 mM 0.0182 mL 0.0912 mL 0.1823 mL 0.4558 mL
    80 mM 0.0137 mL 0.0684 mL 0.1367 mL 0.3418 mL
    100 mM 0.0109 mL 0.0547 mL 0.1094 mL 0.2735 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Rapamycin
    目錄號(hào)：
    HY-10219
    需求量：